Insulet Offers Welcome Program for Animas® Users to Try Omnipod® Insulin Management System at Zero Cost
October 06 2017 - 11:02AM
Business Wire
Insulet Corporation’s (NASDAQ: PODD) (Insulet or the
Company), the leader in tubeless insulin pump technology with its
Omnipod® Insulin Management System (Omnipod System), is
offering the Omnipod® Welcome Program for existing Animas®
insulin pump users as part of the Company’s commitment to the
diabetes community. This program provides users with a no cost
trial of the Omnipod System.
This press release features multimedia. View
the full release here:
http://www.businesswire.com/news/home/20171006005566/en/
“We are offering this program to help ensure people with
diabetes have a choice when it comes to their treatment options,”
said Bret Christensen, Chief Commercial Officer. “This zero cost
trial is a simple way for Animas users to explore the only tubeless
insulin delivery option in the United States. We realize this is a
challenging time for Animas customers and Insulet is deeply
committed to providing access to Omnipod and its unique benefits
enjoyed by more than 100,000 customers across the globe.”
The Omnipod System is designed for all insulin-requiring
patients and is the number one pediatric preferred pump in the
United States1. Adoption of the Omnipod System is rapidly expanding
across the globe due to Omnipod’s unique tubeless design,
significant quality of life benefits, and the flexibility to
utilize the latest Continuous Glucose Monitoring (CGM) technology
available. The Omnipod System’s differentiated design provides up
to 72 hours of nonstop, discreet insulin delivery, a remote bolus
feature, and many options for site rotation. Additionally, it
eliminates the burden associated with multiple daily injections and
the complexities associated with traditional tubed pumps.
Animas users can experience these benefits through Insulet’s
Welcome Program, which includes a free Omnipod System, built-in
blood glucose meter, and 30 days of supplies at zero cost.
For full offer details and to get started, Animas patients
should call the Customer Care Team at 1-888-643-8763. Offer terms
and conditions are subject to change. Please click here to access
the flyer with additional promotion details.
1 dQ&A Q3 2016 Patient Panel Survey. Share of parents
of children with type 1 diabetes on an insulin pump who had chosen
the Omnipod® was higher than for other pumps. Statistical
significance of results calculated at the 95% confidence level.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD) is an innovative medical
device company dedicated to making the lives of people with
diabetes easier. Insulet seeks to expand the use of
insulin pump therapy with its Omnipod Insulin Management System
among people with insulin-dependent diabetes. The Omnipod System is
a revolutionary and easy-to-use tubeless insulin pump that provides
up to three days of non-stop insulin delivery, without the need to
see or handle a needle. Insulet's Delivery Systems
business partners with global pharmaceutical and biotechnology
companies to adapt the Omnipod technology platform for the delivery
of subcutaneous drugs across multiple therapeutic areas. Founded in
2000, Insulet Corporation is based
in Billerica, Massachusetts. For more information, please
visit: http://www.myomnipod.com.
Forward-Looking Statement:
This press release may contain forward-looking statements
concerning Insulet's expectations, anticipations,
intentions, beliefs or strategies regarding the future. These
forward-looking statements are based on its current expectations
and beliefs concerning future developments and their potential
effects on Insulet. There can be no assurance that future
developments affecting Insulet will be those that it has
anticipated. These forward-looking statements involve a number of
risks, uncertainties (some of which are beyond its control) or
other assumptions that may cause actual results or performance to
be materially different from those expressed or implied by these
forward-looking statements, and other risks and uncertainties
described in its Annual Report on Form 10-K, which was filed with
the Securities and Exchange Commission on February
28, 2017 in the section entitled "Risk Factors," and in its
other filings from time to time with the Securities and
Exchange Commission. Should one or more of these risks or
uncertainties materialize, or should any of its assumptions prove
incorrect, actual results may vary in material respects from those
projected in these forward-looking
statements. Insulet undertakes no obligation to publicly
update or revise any forward-looking statements.
© 2017 Insulet Corporation and Omnipod are trademarks
or registered trademarks of Insulet Corporation. All rights
reserved. All other trademarks are the property of their respective
owners. The use of third party trademarks does not constitute an
endorsement or imply a relationship or other affiliation.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171006005566/en/
Investor Relations and Media Contact:Insulet
CorporationDeborah R. Gordon, 978-600-7717Vice President, Investor
Relations and Corporate Communicationsdgordon@insulet.com
Insulet (NASDAQ:PODD)
Historical Stock Chart
From Apr 2024 to May 2024
Insulet (NASDAQ:PODD)
Historical Stock Chart
From May 2023 to May 2024